Introduction

▼
This review describes the early development concept for a novel subcutaneous (SC) formulation for the humanized monoclonal antibody (mAb) trastuzumab (Herceptin TM ). Trastuzumab is approved as an intravenous (IV) formulation to treat patients with early and metastatic breast cancer [ 1 ] and metastatic gastric and gastroesophageal junction (GEJ) cancers [ 2 ] whose tumors over-express the human epidermal growth factor receptor 2 (HER2). IV infusion of trastuzumab is a well-established treatment modality. SC administration, however, may overcome a number of disadvantages related to the currently approved route of administration [ 3 , 4 ] . Being less invasive and with an injection duration of approximately 5 min, SC dosing is expected to be more convenient for patients compared to IV infusion which takes about 30-90 min depending on the treatment cycle and individual tolerability. Especially, patients on single agent mAb therapy [ 5 ] and those receiving trastuzumab in combination with oral chemotherapy [ 6 -8 ] are expected to benefi t from this alternative route of administration. While IV infusion is typically administered in a hospital or physician's offi ce, SC administration centrated antibody solution still results in a comparatively high SC dosing volume of 5 mL.
To enable SC injection of this higher volume, trastuzumab was coformulated with recombinant human hyaluronidase (rHuPH20), an enzyme that temporarily degrades hyaluronan in the interstitial space, thereby facilitating the spreading of injected volumes over a greater area [ 16 , 17 ] . Co-formulation of rHuPH20 with therapeutic proteins allows SC injection volumes to be increased and potentially enhances absorption of the therapeutic protein into the systemic circulation [ 18 , 19 ] . Hyaluronidase products of animal origin have been used clinically for over 60 years [ 20 ] . Hyaluronidase increases the permeability of SC tissue through the hydrolysis of hyaluronic acid, a polysaccharide found in the intercellular ground substance of connective tissue, and of certain specialized tissues, such as the umbilical cord and vitreous humor. The hydrolysis of hyaluronic acid temporarily decreases the viscosity of the interstitial gel-like matrix and promotes transport of injected fl uids or of localized transudates or exudates, thus facilitating their absorption. The safety and effi cacy of hyaluronidase products have been widely established [ 21 , 22 ] . More recently, the FDA approved rHuPH20 (Hylenex ® recombinant (hyaluronidase human injection)) for the following indications: as an adjuvant to increase the absorption and dispersion of other injected drugs, for hypodermoclysis, as an adjunct in SC urography for improving resorption of radiopaque agents. The increased purity of the preparation and the authentic human amino acid sequence of rHuPH20 are thought to be associated with a reduced risk of immunogenicity [ 23 ] .
Scientifi c Basis for Dose Selection Approach
▼
The aim of the dose fi nding studies was to select a SC dose that achieves trastuzumab serum trough concentrations (C trough ) at least as high as those with the approved IV formulation while maintaining the clinical dosing frequency. The selected dose was subsequently to be confi rmed by a formal pharmacokinetic noninferiority test as co-primary endpoint in a Phase 3 study (Section 6.4). The key assumption supporting this dose selection approach is that clinical response is driven by the concentration of a given mAb and that optimal effi cacy is obtained when all accessible target sites are saturated [ 24 -27 ] .
Selection of IV trastuzumab doses
Trastuzumab is approved as a once-weekly (q1w) or 3-weekly (q3w) dosing regimen, with the q1w regimen developed initially [ 28 , 29 ] . The dose levels for these regimens were selected from xenograft models to exceed the target concentration that showed a superior outcome against tumor growth (data on fi le F. Hoff mann-La Roche Ltd) [ 30 ] . These studies supported the selection of 20 μg/mL as a targeted minimum trastuzumab C trough . A loading dose was used for the IV formulation in order to obtain trastuzumab concentrations in the target range more rapidly. The q1w loading (4 mg/kg) and maintenance (2 mg/kg) doses achieve this trough concentration in the majority of patients for the entire duration of treatment ( • ▶ Table 1 , data on fi le F. Hoffmann-La Roche Ltd). Subsequently, a q3w IV dosing regimen was developed on the basis of mimicking the average exposure obtained with the q1w regimen [ 31 ] . This less frequent dosing regimen consists of an 8 mg/kg loading dose followed by q3w 6 mg/kg maintenance doses. Based on a population pharmacokinetic analysis with data primarily from the MBC setting, the predicted median C trough (over a period of 3 weeks at steady-state) for the q1w and q3w regimens are 64.9 and 47.3 mg/L, respectively ( • ▶ Table 1 , data on fi le F. Hoff mann-La Roche AG). With these steady-state median concentrations, more than 90 % of the patients exceed the target C trough of 20 μg/mL at the approved IV dose levels.
Concept of target site saturation to support selection of trastuzumab SC dose
Trastuzumab specifi cally binds to HER2 expressed on mammalian cells. A population pharmacokinetics model for trastuzumab showed that it exhibits linear pharmacokinetics in the range of clinical serum concentrations [ 32 , 33 ] , indicating saturation of accessible target sites. This hypothesis is supported by data published by Mager et al. [ 34 ] , showing that the specifi c and saturable interaction of antibodies with the target receptor infl uences their disposition. Once accessible target sites are saturated, linear pharmacokinetics are observed. The conclusion that the approved IV trastuzumab regimens lead to saturation of accessible target sites (HER2 receptors) and, therefore, to optimal clinical effi cacy is supported by a plateau eff ect in the dose-effi cacy relationship that has been described previously [ 35 ] . No statistically signifi cant diff erence in response rate was seen in MBC patients between the approved q1w IV regimen (4 mg/kg loading dose; 2 mg/kg maintenance dose) and a second unapproved q1w IV regimen using a double dose (8 mg/ kg loading dose; 4 mg/kg maintenance dose) ( • ▶ Table 2 ).
Based on the above considerations, the dose for the q3w SC trastuzumab formulation was selected with the aim of achieving trastuzumab serum trough concentrations at least as high as those obtained with the q3w IV trastuzumab formulation. It is therefore expected that trastuzumab serum concentrations upon SC administration that are non-inferior to those after IV administration would result in a comparable clinical benefi t. The Phase 3 HannaH trial (BO22227) comparing effi cacy, pharmacokinetics and safety of the IV and SC formulations in patients with HER2-positive breast cancer (neo-adjuvant followed by adjuvant setting) has been conducted to confi rm this hypothesis (Section 6.4).
Nonclinical Pharmacology and Pharmacokinetics
Studies Supporting Development of the SC Formulation for Trastuzumab
▼
The nonclinical pharmacology and pharmacokinetics studies were conducted to support (i) the bridging from the approved IV administration of trastuzumab to the SC administration route and (ii) the selection of the rHuPH20 concentration in the trastuzumab SC formulation.
Preclinical pharmacology studies IV/SC bridging study with trastuzumab in a mouse xenograft model
A pharmacology study in a mouse xenograft model was designed to bridge between the IV and SC dosing regimens and to demonstrate similar pharmacodynamic activity of trastuzumab at the same minimum serum concentration after IV and SC administration, i. e., irrespective of the administration route. BALB/c nu/ nu mice were transplanted subcutaneously with the non-small cell lung cancer cell line Calu-3, which has high expression of HER2. This xenograft model was successfully used in our laboratory for pharmacology studies with the anti-HER2 antibodies pertuzumab and trastuzumab [ 36 , 37 ] . Approximately 4 weeks after cell transplantation, mice (n = 10 per dose group) were treated with 0, 1, 3 or 10 mg/kg trastuzumab by either SC or IV administration once weekly for a period of 6 weeks. SC administration was done on the fl ank contralateral to the tumor xenograft. The trastuzumab SC formulation contained 4 600 U/ mL rHUPH20 to aid in dispersion and uptake of trastuzumab from the SC space. The trastuzumab dose levels for SC and IV dosing were selected based on a previous single dose IV and SC pharmacokinetics study in mice (data not shown). Simulated multiple-dose pharmacokinetics profi les indicated that SC and IV dosing at the same dose level yield about 50 % lower maximum trastuzumab serum concentrations following SC administration, while trastuzumab trough levels were similar for both dosing routes. Thus, dose levels of 1, 3, and 10 mg/kg were chosen for both SC and IV administration. Tumor size was assessed throughout the treatment period and was correlated with route, dose and terminal serum trough levels of trastuzumab.
Tumor growth inhibition tended to be dose dependent ( • ▶ Fig. 1 ).
Following administration of trastuzumab at a dose of 1 mg/kg by SC or IV administration, there was no apparent tumor growth inhibition (average ± SD trough serum concentrations were 0.62 ± 0.36 and 0.73 ± 0.42 μg/mL after IV and SC administration, respectively). Following IV or SC administration of 3 mg/kg trastuzumab, tumor growth inhibition was evident with no diff erence between dose routes (median tumor growth inhibition 38 % and 39 % after IV and SC dosing determined on day 71 after tumor cell inoculation). Average trastuzumab C trough ( ± SD) prior to the last treatment was similar for both routes of administration (9.4 ± 5.4 and 10.4 ± 11.9 μg/mL after IV and SC dosing, respectively). Also at 10 mg/kg IV or SC trastuzumab, tumor growth inhibition was not signifi cantly diff erent between dosing routes. A trend towards higher tumor growth inhibition after IV administration (median tumor growth inhibition 66 % and 48 % after IV and SC dosing determined on day 71 after tumor cell inoculation) was consistent with a trend towards higher serum trough concentrations after IV dosing (95.7 ± 26.5 and 61.3 ± 33.8 μg/mL after IV and SC dosing, respectively). The trend to lower average exposure and tumor growth inhibition after SC administration is probably a chance result due to very low exposure in a few mice of the 10 mg/kg SC dose group. Overall, the results of the study suggest that the SC vs. IV dosing routes do not infl uence trastuzumab effi cacy in this xenograft model given that similar trastuzumab trough concentrations are reached. ) was determined twice weekly and is shown as median and interquartile range (n = 9-10 animals per group).
Dye dispersion study in mice
Hyaluronidases (both animal-derived and rHuPH20) can be used in 2 diff erent administration modes to facilitate SC administration: (i) sequential administration of hyaluronidase followed by administration of the drug, or (ii) concomitant administration of hyaluronidase and drug in a co-formulation. In the approved setting, rHuPH20 (Hylenex™) is pre-injected to allow cleavage of hyaluronan prior to subsequent infusion of larger volumes of SC formulations, while the SC trastuzumab formulation contains rHuPH20 as an excipient. We hypothesized that the concomitant administration in a co-formulation as in the trastuzumab SC formulation would require higher hyaluronidase doses as compared to sequential administration to achieve the same permeation enhancing eff ect. Dye dispersion studies are an established approach to study the permeation enhancing eff ects of hyaluronidases [ 19 , 38 ] . A dye dispersion study in nude mice was performed to compare permeation enhancing eff ects of rHuPH20 either following sequential administration of rHuPH20 and a tracer dye or following administration of a co-mixture of tracer dye and rHuPH20. This dye dispersion study was conducted using the intradermal (ID) route. This route was selected to facilitate visualization of dye dispersion and to accommodate anatomical differences between human and non-human subcutis. The subcutis in furred animals like rodents gives little resistance to bulk fl uid fl ow [ 19 ] . By contrast, the ID space in rodents provides resistance to bulk fl uid fl ow and, thus, is a closer approximation to the anatomical resistance to bulk fl uid fl ow in the SC space of humans. The dye dispersion experiment in NCR nu/nu mice (Taconic Laboratories, USA) was conducted as described elsewhere [ 17 ] . rHuPH20 (100 U/mL, total dose 2 U) was injected ID at 1, 5, and 15 min prior to an ID injection of Trypan Blue dye (n = 6 mice/ cohort). The dye dispersion area was then measured at 1, 2.5, 5, and 20 min post ID injection of dye. Dye dispersion areas from sequentially delivered rHuPH20 and Trypan Blue dye were compared to dye dispersion areas following a co-mixture ID injection of Trypan Blue with increasing doses of rHuPH20 (100, 500, and 5 000 U/mL, total doses 2, 10 and 100 U, respectively). A statistically signifi cant, dose-dependent, increase in dye dispersion area was observed with the co-mixture cohorts of 2, 10 and 100 U (100, 500, and 5 000 U/mL) of rHuPH20 ( • ▶ Fig. 2 ). In comparison, dye dispersion areas of animals injected with 2 U (100 U/mL; 0.88 μg/mL) of rHuPH20 followed by a subsequent sequential injection of Trypan Blue dye at 1, 5, and 15 min were not statistically diff erent from each other, suggesting that by 1 min, the majority of the local dispersion reaction had reached completion. Sequential injections yielded faster dye spreading as compared to co-mixture administration of the same enzyme dose. These results demonstrate that 5-50-fold more rHuPH20 is required in a co-mixture solution to approach maximal spreading eff ects as observed with sequential administration, in the time frame relevant for SC injections, e. g., 5 min or less. Thus, administration of co-mixture solutions containing 500-5 000 U/ mL rHuPH20 achieved a dispersion profi le similar to sequential administration of a solution with 100 U/mL rHuPH20 followed by Trypan Blue dye injection.
Pharmacokinetic study in minipigs
A pharmacokinetic study with trastuzumab SC in minipigs explored the eff ect of various rHuPH20 concentrations on the SC absorption of trastuzumab in order to guide rHuPH20 concentration selection for the formulation used in the fi rst clinical study with trastuzumab SC. The minipig was chosen because its skin and the texture of the SC tissue are considered to be similar to those of humans with a fi brous tissue network connecting dermis and deep fascia/muscle [ 39 ] . In addition, the minipig has been demonstrated to be a predictive model for human pharmacokinetics of mAbs after both IV and SC administration [ 40 ] . Female Göttingen minipigs (Ellegaard Göttingen Minipigs A/S, Dalmose, Denmark) (n = 5/dose group) received a single SC dose of trastuzumab at 108 mg/animal (about 13-14 mg/kg) containing either 0, 2 000 or 6 000 U/mL rHuPH20. Another group received a SC dose of trastuzumab at 216 mg/animal (about 26.7 mg/kg) containing 2 000 U/mL rHUPH20 to explore doselinearity of SC absorption. Serum concentrations of trastuzumab were analyzed with a specifi c ELISA.
• ▶ Fig. 3 shows the average serum concentration-time profi les for the SC dose groups dosed at 108 mg/animal. After SC administration, trastuzumab absorption in minipigs was more rapid with rHuPH20-containing formulations. Median time to maximum serum levels (T max ) was shortened from 72 h without rHuPH20 to 24 h for all rHuPH20-containing formulations. Average maximum trastuzumab serum levels ( ± SD) for the rHuPH20-containing formulations trended towards an increase relative to the levels obtained for the formulation without rHuPH20 (101 ± 21.7, 126 ± 13.2 and 129 ± 6.78 μg/mL at 0, 2 000, and 6 000 U/mL rHuPH20, respectively, at 108 mg trastuzumab).
Compartmental pharmacokinetic modeling was done using a non-linear mixed-eff ects model. The structural model was composed of 2 compartments with both a linear clearance and saturable clearance from the fi rst compartment ("serum compartment") and linear inter-compartment exchange as described elsewhere [ 40 ] . Additionally, fi rst-order absorption from an absorption site compartment was assumed in the case of SC administration. For model development, additional data after IV administration of trastuzumab to minipigs were used (data not shown). Compartmental pharmacokinetic modeling revealed approximately 2-fold higher estimates for the absorption rate constants associated with the rHuPH20-containing formulations relative to the rate constant associated with the control formulation without rHuPH20 (0.828, 1.66, and 1.71 day − 1 at 0, 2 000 and 6 000 U/mL rHuPH20). Thus, there was no further increase in absorption rate when increasing the rHuPH20 concentration from 2 000 to 6 000 U/mL. The similar absorption rate constants at these rHuPH20 concentrations are consistent with the superimposable trastuzumab serum concentration-time curves from these formulations during the absorption phase ( • ▶ Fig. 3 ). Compartmental modeling using a population PK approach (non-linear mixed eff ects model) revealed no relevant diff erence in the absorbed fraction of trastuzumab across formulations. The estimate for the absorbed fraction of trastuzumab was 85.4 ± 2.6 % when utilizing data from all SC dose group (mean ± standard error of the population mean parameters estimated from compartmental PK analysis). An increase in the absorbed fraction from rHuPH20 containing formulations was not expected considering the high absorbed fraction of trastuzumab without rHuPH20. Non-compartmental PK analysis suggested a higher interindividual variability in the fraction absorbed/bioavailaibility as compared to the compartmental PK analysis. Thus, for the trastuzumab formulation containing 2 000 U/mL rHuPH20 SC bioavailability estimates ranged from 67 to 94 %, while individual fraction absorbed estimates from compartmental PK analysis ranged from 73 to 85 %. The higher variability in the estimates from non-compartmental analysis may be due to the fact that due to the parallel group design of the study the SC bioavailability estimates from non-compartmental analysis refl ect interindividual diff erences in both absorption and disposition kinetics. Doubling of the trastuzumab dose had no obvious impact on the SC absorption rate (or process). At the 216 mg trastuzumab SC dose, exposure was roughly twice as a high as that for the 108 mg trastuzumab SC dose when using the same formulation containing 2 000 U/mL rHuPH20 (average AUC 0-672 h ± SD: 29 600 ± 3 360 and 73 600 ± 15 200 μg · h/mL at 108 and 216 mg trastuzumab). Overall, these data from minipigs demonstrate an approximately 2-fold more rapid absorption of SC administered trastuzumab from rHuPH20-containing formulations compared to the formulation without rHuPH20. This eff ect on the absorption rate was similar with both of the tested rHuPH20 concentrations, i. e., the increase in the rHuPH20 concentration from 2 000 to 6 000 U/mL did not lead to a further absorption enhancement. These data support the use of 2 000 U/mL rHuPH20 in the clinical trastuzumab SC formulation.
Clinical
▼
The clinical studies conducted to bridge from the approved IV to the SC administration route were designed to defi ne the SC dose required to achieve trastuzumab serum trough concentrations at least as high as with IV administration, to subsequently demonstrate bio-non-inferiority (non-inferior C trough ) and to provide supportive effi cacy data. In addition to systemic side eff ects, special focus was on injection reactions related to SC administration of 5 mL. The formation of anti-drug antibodies (ADAs) and their potential impact on the exposure to trastuzumab and correlation with adverse events has been monitored throughout the clinical program, as the route of absorption might impact the formation of ADAs [ 41 ] . The Phase 1 dose fi nding study that formed the basis for the clinical bridging approach from the approved q3w IV to the q3w SC formulation is described in the following section.
Clinical dose fi nding study
The aims of the clinical dose fi nding study were to support selection of the SC dose of trastuzumab expected to result in trastuzumab serum trough concentrations at least as high as those achieved with the IV formulation and to assess and compare the safety and tolerability of IV and SC dosing [ 42 ] , ( • ▶ Table 3 ). The open-label study was conducted in both healthy male volunteers and female patients with HER2-positive early breast cancer (EBC) in the adjuvant setting.
To avoid under-dosing patients during dose selection, in part 1 of the trial pre-defi ned SC doses were initially studied in healthy male subjects. It was expected that the pharmacokinetics profi le in female patients in the adjuvant setting was comparable to that in male subjects, as tumor tissue that may have aff ected trastuzumab elimination was removed. To be able to account for potential diff erences in the pharmacokinetics profi le in the 2 populations, 2 cohorts, 1 consisting of 6 female patients (Cohort 1) and the other of 6 healthy male subjects (Cohort 2) received a single 6 mg/kg dose of the approved IV formulation. 3 diff erent SC dose levels were subsequently studied in an adaptive fashion in 3 cohorts of 6 healthy male subjects each. The SC trastuzumab dose levels as well as the rHuPH20 concentration of 2 000 U/mL were guided by preclinical animal pharmacology and pharmacokinetics studies (Section 4). As the SC bioavailability in the minipig was approximately 85 % with a comparably large inter-subject variability (range 67 -94 % for the trastuzumab formulation containing 2 000 U/mL rHuPH20), SC doses were pre-selected to cover the observed range of bioavailability. The initially selected trastuzumab SC doses of 6 and 10 mg/kg (cohorts 3 and 4) assume a SC bioavailability of 100 % and of 60 %, respectively. Following interim non-compartmental pharmacokinetics analysis from cohorts 1, 2, 3, and 4, cohort 5 was opened, in which healthy male subjects received an adjusted dose of 8 mg/kg that was expected to result in comparable trastuzumab serum trough concentrations to the 6 mg/kg IV dose. In part 2 of the study, 40 patients with HER2-positive EBC in the adjuvant setting were administered either the SC dose of 8 mg/ kg (n = 20) or a higher dose of 12 mg/kg (n = 20) to cover a greater range of exposure, which was considered relevant in terms of assessing systemic and local adverse events in the target patient population prior to entering into a larger Phase 3 trial.
Pharmacokinetics, safety and tolerability results: SC dose fi nding in humans
Detailed study results from the dose fi nding study have been reported previously [ 42 ] . SC administration of trastuzumab was generally well tolerated. Most AEs (72 %) were mild in severity.
There was no apparent dose-related increase in AEs receiving SC trastuzumab. In patients receiving SC trastuzumab, 18 administration site AEs were reported, the majority of which were of mild intensity (erythema [n = 7], discolouration [n = 5], injection site swelling [n = 2], injection site discomfort [n = 1], injection site reaction [n = 1]). There were 2 instances of moderate injection site pain. There were no clinically signifi cant changes from time-matched baseline values in ECG parameters following doses of the study drug. There were no deaths, serious AEs, treatment withdrawals due to AEs or laboratory abnormalities, or dose modifi cations in this study.
• ▶ Table 4 shows the trastuzumab serum pharmacokinetics following IV and SC administration. Exposure (AUC 0-inf ) in patients receiving 8 mg/kg SC trastuzumab was comparable to that in patients receiving 6 mg/kg IV trastuzumab (1 800 day*μg/mL vs. 2 090 day*μg/mL), indicating a SC bioavailability of approximately 80 %, comparable to the results from the study in minipigs. At the same dose level, trastuzumab serum concentrations measured at 22 days post-dose with 37.8 μg/mL and 27.5μg/mL were slightly higher with the SC compared to the IV dose, respectively. The corresponding coeffi cients of variation (CV %) were with 27.5 % and 27.1 % in the same range, indicating a comparable variability in trastuzumab serum concentrations following both routes of administration. As expected, the C max following the 8 mg/kg SC dose was 88.4 *μg/mL which was markedly lower compared to the IV dose of 6 mg/kg (185 *μg/mL). C max and AUC did not appear to deviate from dose proportionality over the range of SC trastuzumab doses administered (6-12 mg/kg) in both Part 1 and Part 2 [ 42 ] . A total of 8 out of 58 (14 %) participants who had been administered subcutaneous trastuzumab had a positive test result for Table 3 Cohorts in Phase 1 dose fi nding study. HMVs, healthy male volunteers; IV, intravenous; SC, subcutaneous. a. Receiving the approved IV infusion dose for trastuzumab. b. Dose level selected from Part 1 that had resulted in exposure that is comparable with the approved IV infusion dose of 6 mg/kg trastuzumab. c. Dose level selected to cover a larger range of exposure [ 46 ] . Table 4 Mean ( % CV) trastuzumab serum pharmacokinetic parameters [ 46 ] . CV, coeffi cient of variation; HMVs, healthy male volunteers; IV, intravenous; SC, subcutaneous.
Cohort
Cohort 1 HMVs IV Cohort 2
Patients IV anti-trastuzumab antibodies following a confi rmatory binding assay. 2 of these participants were tested positive at 5 months post-administration. The AE and pharmacokinetics profi les in participants with a positive test result for anti-trastuzumab antibodies were in the range of the study population. Due to a lack of an available assay at the time of conducting the study, no neutralizing anti-trastuzumab assay was performed. All participants' samples were negative for neutralizing anti-rHuPH20 antibodies. As the formation of anti-trastuzumab antibodies may depend on the dosing regimen, the frequency of anti-trastuzumab antibodies and the potential implications are investigated further in the Phase 3 HannaH study.
Fixed SC dose
While intravenously-administered trastuzumab is dosed on a weight-adjusted basis (8 mg/kg loading dose followed by q3w maintenance doses of 6 mg/kg), in the Phase 3 study, the SC formulation was given at a fi xed dose for all patients. This fi xed dose was selected using the pharmacokinetics data from the Phase 1 dose-fi nding study applying a modeling and simulation approach (data on fi le F. Hoff mann-La Roche). The analysis indicated that a dose of 600 mg q3w would result in non-inferior C trough at cycle 8 in comparison to the 8 mg/kg loading dose followed by q3w maintenance doses of 6 mg/kg. Predicted C trough values at cycle 1 following SC dosing did exceed the trastuzumab serum target concentration of 20 μg/mL and were comparable to those achieved with the IV loading dose, omitting the need for a loading dose (see section 4.1). Historically, anticancer agents were usually dosed on a weightor body-surface area-adjusted basis. This practice is a result of a scale-up from animal toxicology studies to the human situation [ 43 , 44 ] . Attempts have been made to develop novel mAbs with a fi xed dose. Application of a fi xed dose would avoid potential dose calculation errors and generally reduce health care professional's resources related to prescribing and administration of the drug, as well as manufacturing, storing and shipping costs of the formulation [ 45 -47 ] . The use of a fi xed dose of trastuzumab is supported by a recent simulation study by Wang et al. [ 48 ] that compared the performance of body size-based and fi xed dosing in reducing pharmacokinetics and/or pharmacodynamics variability in adults for 12 intravenously administered monoclonal antibodies (mAbs) with published population pharmacokinetics and/or pharmacodynamics models, including IV trastuzumab. 
Phase 3 HannaH trial
HannaH is a Phase 3, open-label study involving 596 women with HER2-positive early breast cancer. The study was designed to compare trastuzumab serum concentrations (C trough ), effi cacy (pathological complete response, pCR) and safety of trastuzumab SC to that of trastuzumab IV ( • ▶ Fig. 4 ), [ 49 ] . Secondary endpoints included event-free survival and overall survival. The results from this recently analysed study showed that noninferior trastuzumab serum trough concentrations upon SC dosing result in comparable effi cacy (measured as pCR) to the IV regimen. No new safety signals were observed and the SC safety profi le is consistent with the known safety profi le of trastuzumab IV. The HannaH study demonstrated comparable effi cacy of the subcutaneous formulation of trastuzumab to the standard IV infusion of trastuzumab in women with HER2-positive early breast cancer. Data from the study have been presented at the 8th European Breast Cancer Conference in Vienna [ 49 ] and have been submitted in a marketing application to regulatory authorities in the European Union.
SC Trastuzumab Formulation and Injection Device
▼ Herceptin™ (trastuzumab) is currently marketed in Europe in a single-dose vial containing 150 mg trastuzumab in the form of a lyophilized powder (containing the antibody, α,α-trehalose dihydrate, L-histidine and L-histidine hydrochloride and polysorbate 20) which should be reconstituted for infusions with water for injection to yield an injection dose of approximately 21 mg/ml. Another single-dose vial containing 60 mg trastuzumab is used in Japan and Australia. In the USA and many other countries a multiple dosage vial containing 440 mg trastuzumab is marketed. The development of a ready-to-use SC formulation of trastuzumab became feasible with the recent advances in the development of highly concentrated mAb formulations [ 50 , 51 ] and the availability of rHuPH20 that enables rapid SC administration of volumes exceeding 2 mL [ 19 ] . A highly concentrated liquid trastuzumab SC formulation containing 120 mg/mL trastuzumab and 2 000 units (U)/mL rHuPH20 has been developed [ 52 ] . This formulation is administered using a syringe with a hypodermic needle.
As an alternative to manual SC administration by means of a syringe, a new fully automated, single-use injection device (SID) has been engineered to deliver volumes up to 5 mL in approximately 5 min [ 53 ] . The utility of the SID is currently being investigated in the clinical setting. The fl ow rate of 2 mL/min for SC injection with the SID was determined from the clinical dose fi nding study (Section 6.1). In this trial, SC trastuzumab was injected by means of a syringe with a hypodermic needle. Nurses were advised to administer the solution as a bolus injection at a rate that was felt comfortable by the subjects. The resulting median injection rate of 2 mL/ min was consequently selected for the SID. The SID is powered by a battery and has been designed with a built-in automated needle insertion and retraction mechanism to prevent handling injuries. The device is attached to the skin of the patient using an adhesive plaster. Initiation, progression and completeness of delivery can be monitored by the user through the window on the housing and the "Status light" ( • ▶ Fig. 5 ).
Summary and Outlook
▼
This review describes the nonclinical pharmacology/pharmacokinetics and early clinical development of a novel subcutaneous formulation for trastuzumab. Subcutaneous administration of the mAb was feasible by increasing its concentration in the dosing solution and by co-formulating with the recombinant human enzyme hyaluronidase. The enzyme temporarily breaks down hyaluronic acid in the interstitial space at the injection site, which enables the injection of the 5 mL trastuzumab dosing solution.
The basic assumption for bridging from the approved IV to the SC route of administration was that comparable trastuzumab serum trough concentrations would result in comparable efficacy. This assumption was confi rmed both in an animal xenograft model as well as in patients with HER2-positive early breast cancer in the neo-adjuvant/adjuvant setting. The comparably high SC bioavailability seen in minipigs was in the range of that observed in humans.
Diff erent to IV trastuzumab, which is dosed on a weight-adjusted basis, the SC formulation is administered at a fi xed dose in all treatment cycles without the need for a loading dose and independent of a patient's body weight. The trastuzumab SC formulation off ers an alternative to the more invasive and lengthier IV administration. Importantly, for patients who have completed chemotherapy, the SC route might allow spending less time in clinics. The fi xed dose and ready-touse liquid formulation would also reduce pharmacy preparation time, reduce administration costs overall, and should be welcome in institutions with an infusion capacity bottleneck. 
